Ubiquinol

Ubiquinol is the reduced/active form of coenzyme Q10 — your mitochondrial electron-transport workhorse and the principal lipid-soluble membrane antioxidant. A-tier evidence in CHF (Q-SYMBIO mortality benefit), B-tier in statin-induced myalgia, weak-C-tier in healthy young adults. Endogenous synthesis declines starting ~age 30, so supplementation rationale is strongly age-stratified — strongest for 50+/statin-users/cardiac patients, weakest for healthy 20-year-olds. Kaneka QH (Japanese-manufactured stabilized ubiquinol) is the only major commercial source of the reduced form; ubiquinol has ~2-3× the bioavailability of ubiquinone but at 1.5-2× the price. For Dylan: OPTIONAL-ADD low priority — mitochondrial cognitive/recovery angle plausible but ALCAR + astaxanthin + (eventual) idebenone cover the same real estate better, and his endogenous synthesis is at peak. Revisit at 30+, or sooner if statin or cardiac context emerges. If added: 100-200 mg ubiquinol/day with a fat-containing meal.

Coenzyme Q10 (CoQ10, ubiquinone-10, "Q" because of the ubiquitous quinone head, "10" because of the ten-isoprenoid-unit tail) is the canonical lipid-soluble redox cycler of the mitochondrial inner membrane. It is endogenously synthesized via the mevalonate pathway (the same pathway statins block at the HMG-CoA reductase step — hence statin-induced CoQ10 depletion). Plasma and tissue CoQ10 exists predominantly (~95%) in the reduced ubiquinol form (CoQH2) under physiological conditions; the oxidized ubiquinone form is a minor circulating species. The two forms cycle into each other rapidly inside the mitochondrial inner membrane via the Q-cycle.

The mechanistic functions of CoQ10/ubiquinol fall into three layers:

1. Mitochondrial electron transport chain (the canonical role)

Ubiquinol/ubiquinone is the mobile electron shuttle of the inner mitochondrial membrane. It accepts electrons from:

• Complex I (NADH:ubiquinone oxidoreductase): transfers electrons from NADH (the principal product of carbohydrate and amino-acid oxidation) to ubiquinone, reducing it to ubiquinol.
• Complex II (succinate:ubiquinone oxidoreductase, a.k.a. succinate dehydrogenase): transfers electrons from FADH2 (the principal product of fatty-acid β-oxidation and the TCA cycle) to ubiquinone, reducing it to ubiquinol.
• Electron-transferring flavoprotein (ETF) dehydrogenase: another fatty-acid-oxidation electron entry point.
• Glycerol-3-phosphate dehydrogenase (mitochondrial face): electron entry from the glycerol-phosphate shuttle.
• Dihydroorotate dehydrogenase: pyrimidine biosynthesis electron entry.

Once reduced to ubiquinol, the molecule diffuses laterally within the inner membrane and donates electrons to complex III (cytochrome bc1 / Q-cycle), which then passes them to cytochrome c → complex IV → O2. The Q-cycle pumps protons across the inner membrane, building the proton gradient that complex V (ATP synthase) uses to make ATP.

Practical consequence: CoQ10 depletion at any point in this chain reduces ATP synthesis efficiency, increases electron leak, increases superoxide production, and drives oxidative damage. This is the mechanistic basis for the entire CoQ10 supplementation literature.

2. Lipid-soluble membrane antioxidant

Ubiquinol is one of the only lipid-soluble chain-breaking antioxidants that is endogenously synthesized in human tissue (the other major one is α-tocopherol/vitamin E). It quenches lipid peroxyl radicals (LOO·) within mitochondrial inner membranes and circulating LDL particles, terminating lipid peroxidation chain reactions. In LDL specifically, ubiquinol is the first line of defense against oxidative modification — it is consumed before α-tocopherol when LDL is oxidatively stressed in vitro.

Ubiquinol also regenerates α-tocopherol by reducing the tocopheroxyl radical (the form vitamin E takes after it has quenched a lipid radical) back to active tocopherol. This is a vitamin-vitamin synergy that is mechanistically real but clinically subtle.

3. Membrane stabilization, gene expression, and miscellaneous

• Inner-mitochondrial-membrane phospholipid stabilization — particularly cardiolipin, which is essential for ETC supercomplex assembly.
• Modulation of mitochondrial permeability transition pore (mPTP) opening — ubiquinone-binding sites on mPTP subunits influence cell-death thresholds.
• Mild influence on uncoupling proteins (UCP1-3) — relevant to thermogenesis and mild metabolic effects.
• Gene expression effects — CoQ10 status influences expression of hundreds of genes including some involved in inflammation, lipid metabolism, and signal transduction (microarray studies in supplementation trials).

Ubiquinone vs. ubiquinol — the form distinction

This is the practical question for any consumer:

• Ubiquinone (oxidized form): the "classic" CoQ10 supplement. Cheaper, more chemically stable, longer shelf life. Must be reduced to ubiquinol after absorption to be biologically active. Reduction occurs in the gut wall and systemically via NQO1 (NAD(P)H:quinone oxidoreductase 1) and other reductases. Bioavailability is the limiting factor: ubiquinone is poorly water-soluble, and only ~2-3% of an oral dose reaches plasma in many formulations; advanced delivery vehicles (solubilized, nanoparticle, lipid-emulsion) improve this substantially.
• Ubiquinol (reduced form): the bioactive form. Approximately 2-3× the plasma bioavailability of conventional ubiquinone in most head-to-head studies. More chemically unstable (auto-oxidizes to ubiquinone on exposure to air/heat/light) — required Kaneka's stabilization technology to make commercially viable in 2007. More expensive per gram of finished product (typically 1.5-2×). Particularly advantageous in older adults whose NQO1 activity may be reduced and whose ubiquinone-to-ubiquinol conversion efficiency is lower.

Practical claim: for a target plasma CoQ10 increase, ubiquinol gets you there at a lower dose. For most healthy young adults with intact reductase capacity, ubiquinone at a higher dose works essentially the same; for older adults, statin users, and patients with NQO1 polymorphism or mitochondrial-disease conversion deficits, ubiquinol is the meaningfully better choice. The marketing premium for ubiquinol is real but smaller than the price suggests for the average healthy young user.

Endogenous synthesis and age decline

CoQ10 is synthesized de novo in essentially every human cell from tyrosine (head group) and acetyl-CoA-derived isoprenoid units (tail). Synthesis peaks in young adulthood and declines progressively with age — by age 80, tissue CoQ10 levels in heart, skeletal muscle, and brain are 30-50% lower than in young adults. The decline begins gradually in the 30s, accelerates in the 40s-50s, and is well-established by 60+. This age-stratified decline is the single most important fact for prioritizing CoQ10/ubiquinol supplementation.

For Dylan at 20: endogenous synthesis is at peak, tissue stores are saturated, and exogenous supplementation will produce a smaller delta in tissue concentration than the same dose would produce in a 60-year-old. The mechanism doesn't fail — it is just less rate-limiting.